(Q40599181)

21 September 2017

Commentary: effect of flavonoids on normal and leukemic cells (English)

1 reference

21 September 2017

1 reference

2

Zeev Estrov

1 reference

21 September 2017

1

Stefan Faderl

1 reference

21 September 2017

1 June 2003

1 reference

21 September 2017

1 reference

21 September 2017

27

1 reference

21 September 2017

6

1 reference

21 September 2017

471-473

1 reference

STI571: a paradigm of new agents for cancer therapeutics

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900276-X

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900276-X

7 January 2021

Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900276-X

7 January 2021

Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900276-X

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900276-X

7 January 2021

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900276-X

7 January 2021

10.1016/S0145-2126(02)00276-X

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

12648504